Skip to main content
. 2023 Sep 1;23:817. doi: 10.1186/s12885-023-11299-y

Table 3.

Association between PD-L1 expression and clinicopathological characteristics

PD-L1 expression P
Negative CPS (< 10%)
N = 58
n, (%)
Positive CPS (≥ 10%)
N = 43
n, (%)
Age
  < 71 years 22 (44.9) 18 (52.9) 0.376
  ≥ 71 years 27 (55.1) 16 (47.1)
Sex
 Male 36 (73.5) 26 (76.5) 0.803
 Female 13 (26.5) 8 (23.5)
Smoking status
 Smoker 37 (78.7) 26 (83.9) 0.770
 Non-smoker 10 (21.3) 5 (16.1)
Stage group
 Stage II 22 (44.9) 10 (29.4) 0.307
 Stage III 6 (12.2) 7 (20.6)
 Stage IV 21 (42.9) 17 (50)
Metastatic site
 Lungs 6 (12.2) 3 (8.8) 0.731
 Bones 5 (10.2) 2 (5.9) 0.695
 Other 5 (10.2) 5 (14.7) 0.733
Previous treatment
 BCG (+) 11 (68.8) 7 (58.3) 0.698
 BCG (-) 5 (31.3) 5 (41.7)
 Chemotherapy (+) 5 (33.3) 5 (41.7) 0.706
 Chemotherapy (-) 10 (66.7) 7 (58.3)
Histologic type
 Conventional UC 55 (95) 38 (88) 0.28
 UC of special variant 3 (5) 5 (12)
Inflexion/histologic differentiation
 Squamous 15 (26) 10 (23) 0.803
 Glandular 8 (14) 3 (7) 0.187
 Micropapillary 8 (14) 3 (7) 0.695
 Sarcomatoid 0 3 (7) 0.165
 With signet-ring cells 0 1 (2) 0.410
 Microcystic 0 1 (2) 0.410
Molecular subtype
 Basal 14 (64) 12 (719) 0.467
 Luminal 7 (32) 4 (23)

Abbreviations: BCG Bacillus Calmette-Guerin, UC Urothelial carcinoma